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As the prevalence and impact of anemia in patients with cancer have been recognized, clinical guidelines with recommendations
for the use of both transfusions and recombinant human erythropoietin (rHuEPO; epoetin alfa) are continuing to evolve. The
strength of recommendations varies depending on the availability of randomized, controlled clinical trial data for a given endpoint,
which can include transfusion reduction, improvements in hemoglobin (Hb) levels, quality of life (QOL) improvement, or potential
treatment outcome beneﬁts. Clinical studies have shown that epoetin alfa, in doses of 150–300 IU/kg three times a week, con-
sistently increases Hb levels by 1 g/dl at 4 weeks and 2 g/dl at 8 weeks. A prospective, community-based clinical trial has
demonstrated that a once-weekly (QW) regimen of epoetin alfa (40 000–60 000 IU) increases Hb levels by 1.1 g/dl at week 4 and by
1.7 g/dl at week 8. Results from a second prospective, open-label, community-based trial are consistent with these ﬁndings. These
increases are associated with statistically signiﬁcant reductions in transfusion requirements and improvements in QOL. The ques-
tion as to whether epoetin alfa should be given to patients with mild anemia is currently being evaluated in several early-interven-
tion studies (i.e. in patients with mean Hb 12 g/dl). Preliminary results suggest that epoetin alfa, given QW at doses of 40 000–
60 000 IU, prevents Hb decline and may ameliorate deterioration in QOL during chemotherapy in these patients. In addition to
studies evaluating early intervention with epoetin alfa, several ongoing studies are examining new epoetin alfa dosages and
administration schedules in an eﬀort to optimize Hb correction. For example, investigators are evaluating whether regimens with
high initial dosages (60 000–80 000 IU QW) of epoetin alfa, given for a short period of time, may improve hematologic response in
patients with established anemia and whether less frequent maintenance dosing (i.e., 120 000 IU every 3 weeks) is suﬃcient to
maintain the Hb response. If high initial epoetin alfa doses followed by infrequent maintenance dosing proves eﬀective in larger
clinical trials, a variety of more convenient dosing regimens may be available.
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The management of cancer and treatment-related
anemia has been addressed in both anemia- and disease-
speciﬁc cancer treatment guidelines [1,2] as the impact
of anemia is recognized. Anemia is a common con-
sequence of cancer and cancer-related treatment. In a
survey of patients receiving radiation or chemoradia-
tion, approximately 48% of patients have hemoglobin
(Hb) levels <12 g/dl upon presentation; during the
course of therapy, the prevalence may be as high as82%, depending on the type of cancer and the regimens
involved [3]. In the majority of cases, anemia is mild to
moderate (Hb: 9.0–11.9 g/dl) [3] and was thought to be
of little consequence prior to the association with
diminished quality of life (QOL) [4,5]. Anemia causes a
wide spectrum of signs and symptoms ranging from
fatigue to cognitive dysfunction, headache, dizziness,
chest pain, dyspnea, digestive problems, edema, and
heart failure [4,6]. Fatigue has been reported to aﬀect
30% of patients on a daily basis and 59% of patients at
least weekly [5]. It is now well recognized that cancer-
related fatigue is a deﬁnable, multifactorial entity and
anemia with fatigue ﬁts under a much larger QOL con-
struct with many complex causes. Fatigue may impair a1359-6349/$ - see front matter # 2003 Elsevier Ltd. All rights reserved.
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patient’s psychological, social, economic, and physical
well-being, both during the initial treatment and for years
afterward [5]. Multiple studies are underway to ascertain
the eﬀects of anemia on treatment outcome in patients
receiving chemotherapy, radiation therapy, or both.
The primary therapeutic options for reversing anemia
are blood transfusions and administration of recombi-
nant human erythropoietin (rHuEPO, epoetin alfa). The
National Comprehensive Cancer Network (NCCN)
guidelines reiterated the point that blood transfusions
remain the treatment of choice when immediate correc-
tion of anemia is required [2]. In recent years, use of this
approach for moderate anemia has been limited by an
appreciation of the associated risks, such as infection,
nonhemolytic and hemolytic transfusion reactions, iron
overload, reduced immunocompetence (although the
clinical signiﬁcance of this is unknown), and shortages
in the blood supply [2,7]. As a result, the transfusion
‘‘trigger’’ i.e.—the level to which Hb must fall before the
patient receives a transfusion—may be as low as 7–8 g/dl
in some institutions [2].
Mild to moderate anemia is generally treated with
rHuEPO rather than transfusion, and its use has been
addressed in guidelines issued by the American Society
of Hematology and the American Society of Clinical
Oncology (ASH/ASCO) and by the NCCN (1,2). Clin-
ical trials have shown that epoetin alfa, in thrice-weekly
(TIW) regimens of 10 000–20 000 IU or 150–300 IU/kg,
produces a consistent Hb correction of approximately 1
g/dl at week 4 and approximately 2 g/dl at week 8 [8–
10]. Response rates (deﬁned as Hb increase of 52 g/dl
or achievement of Hb level 512 g/dl without transfu-
sion) are approximately 70–74%, with appropriate dose
escalation if required [9,10]. Moreover, according to a
large meta-analysis, epoetin alfa reduces the percentage
of patients who require transfusion by 9–45% in
patients with a mean baseline Hb level of <10 g/dl; by
7–47% in patients whose Hb levels are between 10 g/dl
and 12 g/dl; and by 7–39% in patients with baseline Hb
levels >12 g/dl [11]. These increases in Hb levels have
been associated with statistically signiﬁcant improve-ments in QOL [9,10]. A recent study that compared
clinical trial QOL data obtained using the Functional
Assessment of Cancer Therapy-Anemia (FACT-An)
with normative FACT-An data for the general popula-
tion has shown that the epoetin-alfa–related improve-
ments in QOL measured by this instrument were
clinically meaningful, as well as statistically signiﬁcant
[10,12]. (The FACT-An is a 55-item questionnaire con-
sisting of a 34-item general questionnaire, the FACT-G,
and a 21-item Anemia subscale. Thirteen of the 21 anemia
items comprise a separate fatigue subscale [10]. It is a
QOL instrument now used extensively in clinical studies
involving cancer patients.) Generally, epoetin alfa has
been well tolerated.2. Less frequent dosing
Recommendations for use of epoetin alfa made by
ASH/ASCO were primarily derived from studies in
which epoetin alfa was administered TIW in dosages of
150–300 IU/kg [1]. The NCCN guidelines also include
the more convenient once-weekly (QW) 40 000–60 000
IU epoetin alfa regimen [2].
Data supporting the widely used QW epoetin alfa
regimen of 40 000–60 000 IU subcutaneously (s.c.) are
found in three clinical studies. The ﬁrst was a pro-
spective, multicenter, open-label, nonrandomized, com-
munity-based trial involving 2964 evaluable patients
who were receiving chemotherapy for various solid and
hematologic malignancies [13]. The mean baseline Hb
level was 9.5 g/dl, and all patients were anemic (Hb <11
g/dl). Epoetin alfa was administered sc QW in a dose of
40 000 IU, which was increased to 60,000 IU after 4
weeks if Hb levels did not increase by51 g/dl. This QW
regimen of epoetin alfa increased mean Hb levels by 1.1
g/dl at week 4 and by 1.8 g/dl at study end (Fig. 1)
(P<0.007 for diﬀerence in Hb level from baseline at all
evaluation points, including week 4). The signiﬁcant
increase (P<0.007) in Hb level occurred across all
major tumor types. The overall hematopoietic response
rate (deﬁned as an Hb increase of 52 g/dl or an
achieved Hb of 512 g/dl during the study, with no
transfusions) was 68%. The FACT-An and Linear
Analog Scale Assessment (LASA) measures of QOL
both demonstrated signiﬁcant improvements
(P<0.001), which were associated with increased Hb
levels.
Results have been reported from a second prospective,
open-label, community-based trial in which QW doses of
epoetin alfa (40 000–60000 IU) were administered to 442
patients receiving chemoradiotherapy [14]. Similar
increases in Hb of 1.1 g/dl at week 4 and 2.2 g/dl at study
end were seen and were signiﬁcant (P<0.05) compared
with baseline at week 4 and at all evaluation points
thereafter. The overall response rate was 74% (Table 1).Fig. 1. Mean Hb levels in 2964 cancer patients treated with epoetin
alfa 40 000–60 000 IU once weekly. Adapted with permission [13].P. Sabbatini / EJC Supplements Vol 2 No. 2 (2004) 36–40 37
Recently, a randomized, multicenter, double-blind,
placebo-controlled study enrolled 344 anemic (baseline
Hb 411.5 g/dl and 410.5 g/dl for males and females,
respectively) patients with advanced cancer receiving
chemotherapy and epoetin alfa at 40 000–60 000 IU
QW, with transfusion reduction as the primary end-
point. The need for transfusions was reduced, with 12%
of patients in the epoetin alfa group requiring at least
one transfusion during the 4-month study period versus
27% of patients in the placebo arm (P=0.0008) [15].
These results are consistent with the transfusion rate
reductions observed in the recent major TIW dosing
study in which 24.7% of patients in the epoetin alfa
treatment group versus 39.5% of those in the placebo
group required at least one transfusion after day 28
(P=0.0057) [10].3. Early intervention
Current clinical guidelines for anemia management
note that the evidence supporting the use of epoetin alfa
is strongest for patients whose Hb levels are 410 g/dl
[1,2]. The available published, randomized, controlled
trials at the time of the guideline development did not
have suﬃcient numbers of patients in the Hb 10–12-g/dl
group to evaluate the beneﬁt of early intervention; this
has prompted the initiation of several studies to address
this endpoint, which have now been reported in abstract
form.
In a phase IV, open-label, nonrandomized, multi-
center study, Hudis and colleagues [16] studied the
eﬀects of epoetin alfa (40 000–60 000 IU QW up to 24
weeks) on Hb levels and QOL parameters in patientswith early-stage breast cancer. Final analyses were
based on data from 1597 evaluable patients. At baseline,
the mean Hb level was 12.3 g/dl and impairment of
QOL was minimal. Despite institution of adjuvant
chemotherapy, mean Hb levels had increased by 1.2 g/dl
(P<0.05) by end of study. In a similar, historical-com-
parison population who did not receive epoetin alfa,
mean Hb levels decreased by 2.0 g/dl [17]. Epoetin alfa
was well tolerated in this patient group.
Similarly, O’Shaughnessy et al. [18] conducted a dou-
ble-blind, randomized, placebo-controlled pilot trial of
epoetin alfa, 40 000 IU QW, in 94 breast cancer patients
undergoing four cycles of adjuvant or neo-adjuvant
chemotherapy over 3 months. The mean baseline Hb
level was 12 g/dl. The mean changes in Hb from
baseline to cycle 4 were an increase of 0.8 g/dl in the
epoetin alfa group, compared with a decrease of 2.1 g/dl
in the placebo group (P<0.001). The QOL measures
(LASA and FACT-An) suggested that the epoetin alfa
group had greater improvement of cognitive function
(P=0.011 at cycle 4, as measured by the Executive
Interview [EXIT25]) and less QOL impairment. These
results suggest that early intervention with epoetin alfa
can maintain or increase Hb levels and may maintain or
improve QOL and cognitive function in breast cancer
patients during chemotherapy.
An interim report from a randomized, multicenter,
open-label trial by Straus et al. [19] showed increased
Hb levels and improved QOL with epoetin alfa QW in
patients with mild anemia. Among 179 of 260 enrolled
patients with lymphoma (92%), chronic lymphocytic
leukemia (4%), or multiple myeloma (5%) receiving
chemotherapy, 77 were randomized to receive immedi-
ate treatment with epoetin alfa 40 000 IU QW at the startTable 1
Overview of dosage regimens of epoetin alfa: eﬀects on Hb levels and response rates in recent clinical trialsAuthor/year N Dosage regimen of epoetin alfa Mean baseline
Hb (g/dl)Mean Hb
increase at
4 weeks (g/dl)Mean Hb
increase at
8 weeks (g/dl)Mean ﬁnal Hb
increase (g/dl)Response
rate (%)Littlewood, 2001 [10] 375 150–300 IU/kg TIW for 12–24 weeks 9.9 0.9 1.8 2.2* 70.5aGabrilove, 2001 [13] 2964 40 000–60 000 IU QW for 16 weeks 9.5 1.1 1.7 1.8* 68bChap, 2002 [20]c 11 60 000 IU QW for 16 weeks 9.1 1.1 2.6 1.7 NAO’Shaughnessy, 2002 [18]c 93 40 000 IU QW for 12 weeks >12 0.5 0.6 0.8* NASloan, 2002 [15] 344 40 000–60 000 IU QW for 16 weeks <11.5 for males
<10.5 for femalesNA NA NA NAStraus, 2002 [19]c 179 40 000 IU QW for 16 weeks 12.4 NA NA 0.8* NAHudis, 2003 [16] 1597 40 000–60 000 IU QW for up
to 24 weeks12.3 NA NA 1.2* NAPatton, 2003 [21] 20 60 000 IU QW for 8 weeks, then
120 000 IU Q3W for 16 weeks10.0 1.1 2.8 3.0 NAShasha, 2003 [14] 442 40 000–60 000 IU QW for 16 weeks 9.9 1.1 1.7 2.2* 74bBIW, twice weekly; Hb, hemoglobin; NA, not available; QW, once weekly; Q3W, every 3 weeks; TIW, thrice weekly. *P<0.05 versus baseline.
a Response deﬁned as an increase in Hb 52 g/dL or achievement of an Hb 512 g/dL during the study, with no transfusions given within the
previous 30 days.
b Response deﬁned as a52 g/dL increase in Hb unrelated to transfusion.
c Interim analysis.38 P. Sabbatini / EJC Supplements Vol 2 No. 2 (2004) 36–40
of chemotherapy, while 102 were randomized to obser-
vation during chemotherapy, with epoetin alfa 40 000 IU
QW to be given if Hb declined to <9 g/dl. Baseline Hb
levels (12.41.4 g/dl) increased signiﬁcantly in the
immediate-treatment group (0.82.5 g/dl, P=0.007)
and decreased signiﬁcantly in the observation group
(0.81.0 g/dl, P<0.001; between-group, P=0.005).
The immediate-treatment group reported signiﬁcant
improvements in QOL as measured by total FACT-An
(P=0.036) as well as by the anemia (P=0.047), physical
well-being (P=0.003), and fatigue (P=0.032) subscales
of the FACT-An; changes in total FACT-An and ane-
mia subscale scores were signiﬁcantly correlated with
change in Hb levels, despite the small magnitude of Hb
change (r=0.020; P<0.05). Immediate treatment with
epoetin alfa at the start of chemotherapy also resulted in
a decreased number of clinic visits (P=0.002). These
interim results suggest that QW epoetin alfa beneﬁts Hb
levels and QOL in patients with mild anemia receiving
chemotherapy for hematologic malignancies.4. Optimization of dosing regimens
Other studies are evaluating higher QW doses of
epoetin alfa to determine whether the overall Hb
response can be improved. In an open-label, non-
randomized pilot study, Chap et al. [20] are evaluating
epoetin alfa therapy at a dosage of 60 000 IU QW for up
to 16 weeks in patients receiving chemotherapy. The
dosage is reduced to 40 000 IU QW if the Hb increases
by >1.3 g/dl over a 2-week period. Therapy is withheld
if the Hb level increases to >15 g/dl and is resumed
when the Hb decreases to 13 g/dl. Results are currently
available for 11 patients (mean baseline Hb: 9.11.0 g/dl).
The mean increases in Hb levels in this group were
1.11.5 g/dL at week 4 and 2.62.4 g/dL at week 8. A
randomized comparison is required to determine whe-
ther this Hb response is better than that achieved with
more conventional dosing. No adverse events were
reported.
In another open-label, nonrandomized pilot study,
Patton and colleagues [21] administered epoetin alfa at a
starting dosage of 60 000 IU QW for approximately 2
months to patients undergoing chemotherapy. There-
after, if Hb levels increased by52 g/dl above baseline, a
maintenance dose of 120 000 IU was administered once
every 3 weeks. If Hb levels increased by >1.3 g/dl in a
2-week period, the dosage was decreased to 40 000 IU
QW. If Hb levels increased to >15 g/dl at any time
during the study, therapy was withheld until Hb levels
decreased to 413 g/dl and then resumed at 20 000 IU
QW. The total treatment period was 24 weeks. Data
have been obtained for 20 patients with nonmyeloid
malignancies and a mean baseline Hb of 10.00.8 g/dl.
Mean increase in Hb was 1.1 g/dl at 4 weeks and 2.8 g/dlat 8 weeks. Mean increase in Hb from baseline to last
measurement was 3.0 g/dl. Epoetin alfa was well toler-
ated. Larger-scale trials evaluating this dosing regimen
are warranted.5. Summary
Clinical guidelines are evolving with recommendations
for the use of rHuEPO for the treatment of patients
with moderate anemia. Most of the original data for
epoetin alfa usage was based on 150–300 IU/kg TIW
regimens, which consistently increased Hb levels by
approximately 1 g/dl at 4 weeks and 2 g/dl at 8 weeks,
with overall response rates in the 68–74% range using
appropriate dosing escalation. In addition, open-label
community-based and double-blind, randomized clinical
trials in more than 3000 patients have documented
similar results with a QW epoetin alfa regimen of
40 000–60 000 IU.
Ongoing research is exploring the eﬀects of adminis-
tering epoetin alfa therapy to cancer patients with mild
to moderate anemia. Initial results of these early inter-
vention studies indicate that this approach maintains
normal Hb levels while stabilizing or improving QOL
and cognitive function in patients receiving chemo-
therapy. These ﬁndings have implications for the target
Hb levels to be used for the initiation of epoetin alfa, as
well as the anemia management goals of this therapy,
including reduction of transfusion requirements and
potential avoidance of the deteriorating QOL and phy-
sical well-being associated with anemia.
Interesting results have also been obtained from small
studies evaluating higher starting doses of epoetin alfa
followed by less frequent maintenance doses to optimize
response time and minimize frequency of administration.
Randomized studies are essential and are underway to
evaluate optimal doses, schedules, and thresholds for
initiation of treatment.References
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